CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.
Times cited: 31
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.
Journal of Experimental Medicine.
Times cited: 92